Literature DB >> 17481908

CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.

JoAnn M Gensert1, Oxana V Baranova, David E Weinstein, Rajiv R Ratan.   

Abstract

Recent advances in cancer cell biology have focused on histone deacetylase inhibitors (HDACi's) because they target pathways critical to the development and progression of disease. In particular, HDACi's can induce expression of epigenetically silenced genes that promote growth arrest, differentiation and cell death. In glioma cells, one such repressed gene is the tetraspanin CD81, which regulates cytostasis in various cell lines and in astrocytes, the major cellular component of gliomas. Our studies show that HDACi's, trichostatin and sodium butyrate, promote growth arrest and differentiation with negligible cell death in glioma cells and induce expression of CD81 and cyclin-dependent kinase inhibitor 1A (p21(CIP/WAF-1)), another regulator of cytostasis in astrocytes. Interference RNA knock-down of CD81 abrogates cytostasis promoted by HDAC inhibition indicating that HDACi-induced CD81 is responsible for growth arrest. Induction of CD81 expression through HDAC inhibition is a novel strategy to promote growth arrest in glioma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17481908     DOI: 10.1016/j.nbd.2007.03.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  11 in total

Review 1.  Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.

Authors:  Philip Lee; Ben Murphy; Rickey Miller; Vivek Menon; Naren L Banik; Pierre Giglio; Scott M Lindhorst; Abhay K Varma; William A Vandergrift; Sunil J Patel; Arabinda Das
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

2.  Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Authors:  J Drappatz; E Q Lee; S Hammond; S A Grimm; A D Norden; R Beroukhim; M Gerard; D Schiff; A S Chi; T T Batchelor; L M Doherty; A S Ciampa; D C Lafrankie; S Ruland; S M Snodgrass; J J Raizer; P Y Wen
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

3.  Male CD81 knockout genotype disrupts Mendelian distribution of offspring.

Authors:  Whitney J Mordica; Ryan J Gallagher; Jenna L Kennedy; Stephen K Chapes
Journal:  Comp Med       Date:  2010-06       Impact factor: 0.982

4.  Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase.

Authors:  Hussein Fayyad-Kazan; Redouane Rouas; Makram Merimi; Nabil El Zein; Philippe Lewalle; Fadi Jebbawi; Mohamad Mourtada; Hussein Badran; Mohamad Ezzeddine; Bruno Salaun; Pedro Romero; Arsène Burny; Philippe Martiat; Bassam Badran
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

Review 5.  Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health?

Authors:  Megan W Bourassa; Ishraq Alim; Scott J Bultman; Rajiv R Ratan
Journal:  Neurosci Lett       Date:  2016-02-08       Impact factor: 3.046

6.  CD81 inhibits the proliferation of astrocytes by inducing G(0)/G (1) arrest in vitro.

Authors:  Junfang Ma; Rengang Liu; Huiming Peng; Jieping Zhou; Haipeng Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

Review 7.  HDAC inhibitors and neurodegeneration: at the edge between protection and damage.

Authors:  Karen C Dietz; Patrizia Casaccia
Journal:  Pharmacol Res       Date:  2010-02-01       Impact factor: 7.658

8.  Macrophage cell lines use CD81 in cell growth regulation.

Authors:  Whitney J Mordica; Keith M Woods; Rollie J Clem; A Lorena Passarelli; Stephen K Chapes
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-01-30       Impact factor: 2.416

Review 9.  Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions.

Authors:  Sama F Sleiman; Manuela Basso; Lata Mahishi; Alan P Kozikowski; Mary E Donohoe; Brett Langley; Rajiv R Ratan
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206

10.  HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity.

Authors:  Vivek Sharma; Nitin Koul; Christy Joseph; Deobrat Dixit; Sadashib Ghosh; Ellora Sen
Journal:  J Cell Mol Med       Date:  2010-07-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.